Heathbridge Capital Management Ltd. Has $9.31 Million Position in Haleon plc (NYSE:HLN)

Heathbridge Capital Management Ltd. decreased its stake in Haleon plc (NYSE:HLN) by 8.1% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 1,127,500 shares of the company’s stock after selling 99,500 shares during the period. Haleon makes up 3.9% of Heathbridge Capital Management Ltd.’s investment portfolio, making the stock its 14th biggest position. Heathbridge Capital Management Ltd.’s holdings in Haleon were worth $9,313,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cardinal Capital Management increased its position in Haleon by 2.5% during the 2nd quarter. Cardinal Capital Management now owns 46,231 shares of the company’s stock valued at $382,000 after purchasing an additional 1,140 shares during the period. Endowment Wealth Management Inc. increased its position in shares of Haleon by 9.9% during the second quarter. Endowment Wealth Management Inc. now owns 12,867 shares of the company’s stock worth $106,000 after buying an additional 1,161 shares during the period. Portside Wealth Group LLC raised its stake in Haleon by 2.7% during the second quarter. Portside Wealth Group LLC now owns 44,985 shares of the company’s stock worth $372,000 after buying an additional 1,182 shares during the last quarter. Lester Murray Antman dba SimplyRich lifted its holdings in Haleon by 2.9% in the second quarter. Lester Murray Antman dba SimplyRich now owns 45,519 shares of the company’s stock valued at $375,000 after buying an additional 1,301 shares during the period. Finally, Resonant Capital Advisors LLC boosted its position in Haleon by 7.2% during the second quarter. Resonant Capital Advisors LLC now owns 19,846 shares of the company’s stock valued at $164,000 after acquiring an additional 1,334 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Trading Down 0.7 %

HLN opened at $10.43 on Thursday. The company has a market cap of $47.60 billion, a P/E ratio of 34.75, a price-to-earnings-growth ratio of 3.04 and a beta of 0.26. The company has a fifty day moving average price of $9.50 and a two-hundred day moving average price of $8.77. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 1-year low of $7.70 and a 1-year high of $10.51.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The firm had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. During the same period last year, the company posted $0.08 earnings per share. Analysts predict that Haleon plc will post 0.46 EPS for the current fiscal year.

Haleon Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Thursday, September 19th. Investors of record on Friday, August 16th will be given a $0.0514 dividend. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, August 16th. Haleon’s payout ratio is currently 33.33%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on HLN shares. The Goldman Sachs Group downgraded Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Berenberg Bank started coverage on Haleon in a report on Tuesday, August 6th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.